Ocular Therapeutix Announces First Patient Dosed in Phase 1 Clinical Trial of OTX-CSI for the…
Ocular Therapeutix, Inc. announced that it has dosed the first patients in its Phase 1 clinical trial of OTX-CSI (cyclosporine intracanalicular insert) for the treatment of dry eye…
Read More...
Read More...
